Stock Research for SLP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SLP Stock Chart & Research Data

The SLP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SLP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SLP Due diligence Resources & Stock Charts

The SLP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SLP Detailed Price Forecast - CNN Money CNN View SLP Detailed Summary - Google Finance
Yahoo View SLP Detailed Summary - Yahoo! Finance Zacks View SLP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View SLP Trends & Analysis - Trade-Ideas Barrons View SLP Major Holders - Barrons
NASDAQ View SLP Call Transcripts - NASDAQ Seeking View SLP Breaking News & Analysis - Seeking Alpha
Spotlight View SLP Annual Report - CompanySpotlight.com OTC Report View SLP OTC Short Report - OTCShortReport.com
TradeKing View SLP Fundamentals - TradeKing Charts View SLP SEC Filings - Bar Chart
WSJ View Historical Prices for SLP - The WSJ Morningstar View Performance/Total Return for SLP - Morningstar
MarketWatch View the Analyst Estimates for SLP - MarketWatch CNBC View the Earnings History for SLP - CNBC
StockMarketWatch View the SLP Earnings - StockMarketWatch MacroAxis View SLP Buy or Sell Recommendations - MacroAxis
Bullish View the SLP Bullish Patterns - American Bulls Short Pains View SLP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View SLP Stock Mentions - StockTwits PennyStocks View SLP Stock Mentions - PennyStockTweets
Twitter View SLP Stock Mentions - Twitter Invest Hub View SLP Investment Forum News - Investor Hub
Yahoo View SLP Stock Mentions - Yahoo! Message Board Seeking Alpha View SLP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for SLP - SECform4.com Insider Cow View Insider Transactions for SLP - Insider Cow
CNBC View SLP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SLP - OTC Markets
Yahoo View Insider Transactions for SLP - Yahoo! Finance NASDAQ View Institutional Holdings for SLP - NASDAQ


Stock Charts

FinViz View SLP Stock Insight & Charts - FinViz.com StockCharts View SLP Investment Charts - StockCharts.com
BarChart View SLP Stock Overview & Charts - BarChart Trading View View SLP User Generated Charts - Trading View




Latest Financial News for SLP


Ex-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.32%; Will Trade Ex-Dividend on July 25, 2018
Posted on Tuesday July 24, 2018

LONDON, UK / ACCESSWIRE / July 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on July 25, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 24, 2018. Active-Investors has initiated due-diligence on this dividend stock.


Simulations Plus Subsidiary DILIsym Awarded Grant for up to $1.7 Million For Model Development
Posted on Monday July 23, 2018

DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The grant, coauthored by Dr. Brett Howell (Principal Investigator) and Dr. Bud Nelson, is entitled “Software for predicting a drug’s potential to cause acute kidney injury.” The total award for this Fast Track SBIR grant is up to $1.7 million over the next 18-24 months.


Simulations Plus Enters Funded Research Collaboration with Large European Consortium
Posted on Wednesday July 18, 2018

Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded research collaboration with a large European consortium to further develop and validate the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™. Dr. Viera Lukacova, director of simulation sciences, said: “We are very pleased to have the opportunity to work with the diverse membership of this large European consortium to enhance the GastroPlus TCAT model in support of alternative approaches to animal testing. The model is already being utilized heavily within pharmaceutical companies to support transdermal product development activities.


Edited Transcript of SLP earnings conference call or presentation 10-Jul-18 8:15pm GMT
Posted on Tuesday July 17, 2018

Q3 2018 Simulations Plus Inc Earnings Call


Stock Market & Investing Books

Enter a stock symbol to view the stock details.